Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

Sandoz strikes new five-year deal

 Posted 12 February 2024 AM

Sandoz has announced a new five-year partnership with Biocon Biologics for the exclusive rights to promote, sell and distribute biosimilar versions of two top Roche cancer drugs Herceptin and Avastin in Australia.

Under the deal Sandoz will distribute the Biocon brands, Ogivri, a Herceptin biologic and Abvemy, an Avastin biologic, which the company said had previously been distributed by another pharma. According to the ARTG, the sponsor for Ogivri was Maxx Pharma. 

To see the whole article, please login

Popular

Is 2024 the Year of Burnout?
Albo puts hand up for pharma selfie
Why pharma redundancies hurt
Top specialist in Deep Fake scam
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home